Starling Oncology (STLNW) Cash from Investing Activities (2020 - 2026)
Starling Oncology's (STLNW) quarterly Cash from Investing Activities came in at -$908000.0 in Q2 2026, up 24.83% on a YoY basis from -$727363.4 in Q2 2025, and up 12.86% quarter-over-quarter from -$1.0 million in Q1 2026.
Powered by 
Analysis
Starling Oncology (STLNW) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Starling Oncology (STLNW) has reported Cash from Investing Activities for 7 consecutive years, with -$908000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Investing Activities rose 24.83% year-over-year to -$908000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.6 million (down 149.94% YoY), and the FY2025 full-year result was -$3.1 million, down 106.65% from the prior year.
- Cash from Investing Activities rose to -$908000.0 in Q2 2026 per STLNW's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $24.9 million in Q2 2023 and bottomed at -$87.8 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$1.5 million across 5 years, with a median of -$756000.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 9139.89% in 2022, then surged 1936.43% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$32.6 million in 2022, then soared by 135.7% to $11.6 million in 2023, then sank by 115.09% to -$1.8 million in 2024, then jumped by 39.6% to -$1.1 million in 2025, then gained by 14.34% to -$908000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$908000.0, -$1.0 million, and -$1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.90 Bn | 11.21 Bn | 1.16 Bn | -194.25 Mn |
| 2 | RadNet | 5.50 Bn | 4.77 Bn | 88.08 Mn | -63.55 Mn |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn | -314.72 Mn |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn | -14.20 Mn |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - | -11.46 Mn |
| 6 | Pediatrix Medical | 2.15 Bn | 1.75 Bn | - | 6.02 Mn |
| 7 | Progyny | 2.11 Bn | 1.87 Bn | 89.30 Mn | 3.55 Mn |
| 8 | Surgery Partners | 1.85 Bn | 1.63 Bn | 622.10 Mn | -19.80 Mn |
| 9 | U S Physical Therapy | 1.18 Bn | 1.15 Bn | 41.94 Mn | -6.41 Mn |
| 10 | Starling Oncology | 4.13 Mn | -36.96 Mn | 27.17 Mn | -908,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -908,000.00 |
| Mar 31, 2026 | -1.04 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | -604,000.00 |
| Jun 30, 2025 | -1.21 Mn |
| Mar 31, 2025 | -202,000.00 |
| Dec 31, 2024 | -1.76 Mn |
| Sep 30, 2024 | 10.40 Mn |
| Jun 30, 2024 | 18.18 Mn |
| Mar 31, 2024 | 19.39 Mn |
| Dec 31, 2023 | 11.63 Mn |
| Sep 30, 2023 | 7.71 Mn |
| Jun 30, 2023 | 24.90 Mn |
| Mar 31, 2023 | 18.40 Mn |
| Dec 31, 2022 | -32.57 Mn |
| Sep 30, 2022 | -87.78 Mn |
| Jun 30, 2022 | -10.26 Mn |
| Mar 31, 2022 | -1.00 Mn |
| Dec 31, 2021 | -9.15 Mn |
| Sep 30, 2021 | -950,000.00 |